Arca Biopharma (ABIO) Reports Q2 Loss of $0.10/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ARCA biopharma Announces Second Quarter 2015 Operating Results and Provides Update on Recent Accomplishments
August 11, 2015 4:00 PM EDTGENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation
Phase 2B of GENETIC-AF Projected to Complete Enrollment by Year-End 2016
WESTMINSTER, Colo.--(BUSINESS WIRE)-- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2015, and provided an update on recent accomplishments.
This quarter was productive for ARCA. We strengthened our financial position through a successful equity offering that resulted in net proceeds of approximately $34 million, which we believe... More
